BioSante Pharmaceuticals, Inc. 

(Public, NASDAQ:BPAX)   Watch this stock   
Find more results for BPAX
Nov 17, 2009
BIOSANTE PHARMACEUTICALS INC at Lazard Capital Healthcare Conference
Nov 10, 2009
BIOSANTE PHARMACEUTICALS INC at Merriman Curhan Ford Investor Summit
Nov 9, 2009
Q3 2009 BIOSANTE PHARMACEUTICALS INC Earnings Release
Nov 3, 2009
BIOSANTE PHARMACEUTICALS INC at Oppenheimer & Co. Healthcare Conference
Oct 29, 2009
BIOSANTE PHARMACEUTICALS INC at The 8th Annual BIO Investor Forum - Webcast
Sep 30, 2009
BIOSANTE PHARMACEUTICALS INC Special Stockholders Meeting
Sep 17, 2009
BIOSANTE PHARMACEUTICALS INC at EBD Group BioPharm America Conference
Sep 10, 2009
BIOSANTE PHARMACEUTICALS INC at Rodman & Renshaw Annual Global Investment Conference
More events from AOL Finance »    

Key stats and ratios

Q2 (Jun '09) 2008
Net profit margin -4018.26% -461.01%
Operating margin -4018.26% -476.56%
EBITD margin - -475.42%
Return on average assets -162.99% -71.24%
Return on average equity -232.79% -80.02%
Employees 23 -

Address

111 Barclay Boulevard
Lincolnshire, IL 60069
United States - Map
+1-847-4780500 (Phone)
+1-847-4789152 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance

BioSante Pharmaceuticals, Inc. discussed on blogs

Ranking 1100+ Micro Cap Stocks by Upside Potential - NASD100.com ... - Investor's Resources - NASD100.com - Daily Stock Rankings - 14 hours ago
Ranking Healthcare Stocks by Upside Potential - NASD100.com ... - Investor's Resources - NASD100.com - Daily Stock Rankings - Nov 19, 2009

BioSante Pharmaceuticals, Inc. discussions

  View all discussions »

Description

Biosante Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism. The Company primary products include gel formulations of testosterone and estradiol. It is also engaged in the development of its calcium phosphate nanotechnology (CaP), primarily for aesthetic medicine, vaccines and drug delivery. The Company’s principal products include LibiGel, Bio-T-Gel and Pill-Plus. The Company’s CaP products in development include BioLook, BioVant, BioOral and BioAir. In October 2009, BioSante Pharmaceuticals, Inc. and Cell Genesys, Inc. announced the completion of the merger of Cell Genesys, Inc. with and into BioSante Pharmaceuticals, Inc., with BioSante Pharmaceuticals, Inc. as the surviving company. Pursuant to the merger, BioSante Pharmaceuticals, Inc. has acquired all of the outstanding shares of Cell Genesys, Inc.

Officers and directors

Louis W. Sullivan M.D.
Chairman of the Board
Age: 75
Bio & Compensation - Reuters
Stephen M. Simes
Vice Chairman, President, Chief Executive Officer
Age: 57
Bio & Compensation - Reuters
Phillip B. Donenberg CPA
Chief Financial Officer, Treasurer, Secretary
Age: 48
Bio & Compensation - Reuters
Fred Holubow
Director
Age: 70
Bio & Compensation - Reuters
Ross Mangano
Director
Age: 63
Bio & Compensation - Reuters
Edward C. Rosenow III, M.D.
Director
Age: 74
Bio & Compensation - Reuters
Peter Kjaer
Director
Age: 48
Bio & Compensation - Reuters
Stephen A. Sherwin M.D.
Director
Age: 60
Bio & Compensation - Reuters